VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

USA - Nasdaq - NASDAQ:VRDN - US92790C1045 - Common Stock

32.02 USD

-0.44 (-1.36%)

Last: 12/5/2025, 8:00:01 PM

32.02 USD

0 (0%)

After Hours: 12/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VRDN Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Zacks Investment Research - Mentions: BFRI

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

2 months ago - By: Benzinga

Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts

7 months ago - By: Benzinga

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

a month ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

a month ago - By: Zacks Investment Research - Mentions: IVVD

Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

a month ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Proposed Underwritten Public Offering

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: The Motley Fool

Viridian (VRDN) Q2 Net Loss Widens 55%

4 months ago - By: Zacks Investment Research - Mentions: FATE

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

5 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

7 months ago - By: Zacks Investment Research - Mentions: IOVA

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

9 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

10 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease